Pharma

Your Article Summary

See Latest Articles

AVI BioPharma Under Contract with U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu
AVI BioPharma, 06/23/09

AVI BioPharma, Inc. , a developer of RNA-based drugs, is under contract with the U.S. Defense Threat Reduction Agency for development of one or more nucleotide-based candidate drugs targeting the present epidemic of H1N1 swine flu.

Today in M&A/Partnerships...keeping you current

Receive free subspecialty "5-minute updates" via email

Sanofi-aventis to acquire Oenobiol, French leader in nutritional beauty supplements
Sanofi-aventis, 11/02/09

Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
Nabi Biopharmaceuticals, 11/05/09

New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
Chugai Pharmaceutical Co., 11/04/09

See All of M&A/Partnerships

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09

Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09

Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09

See All of Research & Development